AbbVie is making a roughly $11 billion bet on the next generation of immune-disease drugs. The company agreed to buy Apogee Therapeutics for $135.11 per share in cash, valuing the biotech at about $10.9 billion, the two companies announced on June 22. Apogee shares jumped about 46% on the news.
What AbbVie is buying
Apogee is a clinical-stage biotech — it has no approved products and no sales yet; its value is entirely in experimental drugs moving through human trials. Its lead candidate, zumilokibart, is a long-acting antibody that blocks interleukin-13, a protein that drives the inflammation behind eczema (atopic dermatitis) and asthma, according to BioPharma Dive. Its selling point is convenience: it is engineered so patients might need only a few injections a year, versus the every-other-week dosing of Dupixent, the Sanofi/Regeneron drug that dominates eczema treatment today. Apogee is also developing a combination treatment aimed at asthma and lung inflammation.
Why AbbVie is paying up
The price reflects a premium — the extra amount a buyer pays over a company's market value to win a deal — of roughly 49% to Apogee's prior close, per BioPharma Dive. AbbVie is paying that because it has a hole to fill.
Its arthritis drug Humira was for years the best-selling medicine in the world, generating more than $20 billion annually at its peak. But Humira lost U.S. patent protection in 2023, and biosimilars — cheaper, regulator-approved copies of a biologic drug — have eaten into its sales ever since. AbbVie has been rebuilding around two newer immunology drugs, Skyrizi and Rinvoq, both growing fast. Apogee extends that push deeper into skin and respiratory disease.
The trade-off is time: AbbVie said it does not expect the deal to add to adjusted earnings until 2032, a reminder that it is buying a pipeline, not immediate profit.
The bigger pattern
The deal is the latest in a steady wave of large drugmakers buying smaller biotechs to refill pipelines thinned by patent expirations. Developing a drug in-house is slow and risky; acquiring a company that already has mid-stage (Phase 2) trial data lets a giant skip years of early uncertainty — at a cost. Paying $10.9 billion for a company with no approved product underscores how much the market values differentiated science in crowded, high-demand areas like eczema and asthma.
For AbbVie investors, the reaction was telling: its own shares rose on the news, an unusual move for a buyer spending nearly $11 billion, suggesting the market saw the price as defensible given the pipeline's potential. The deal is expected to close in the third quarter of 2026, subject to Apogee shareholder and regulatory approval. As with any drug still in trials, the ultimate payoff depends on results that have not yet been delivered.
